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Abstract
Background: Liver cancer is a highly lethal cancer with 5 year survival rate of about 18%. This cancer is a leading cause of death
in many countries. As there is not a comprehensive population base study on liver cancer mortality rates by cause in national and
provincial level in Iran. We aimed to estimate the liver cancer mortality rate, its patterns, and temporal trends during 26 years by
sex, age, geographical distribution, and cause.
Methods: We used the Iranian death registration system (DRS), in addition to demographic and statistical methods, to address
the incompleteness and misclassification and uncertainty of death registration system to estimate annual liver cancer mortality
rate. Direct age standardized approach was applied using Iran national population 2015 as a standard population to facilitate the
comparison between the provinces.
Results: Liver cancer age standardized mortality rate in Iran increased by more than four times from 1.18 (95% uncertainty interval;
0.86 to 1.61) deaths per 100,000 person in 1990 to 5.66 (95% uncertainty interval; 4.20 to 7.63) deaths per 100,000 person in 2015.
Male to female age adjusted mortality ratio changed from 0.87 to 1.82 during the 26 years of the study. With increasing age, liver
cancer mortality rate increased in both sex and all provinces. At provincial level, the province with highest mortality rate have 2.96
times greater rate compare to the lowest. Generally, about 71% of mortality at national level is due to hepatitis B and C infection.
Conclusions: In order to reduce liver cancer mortality rate, it is recommended to control main risk factors including chronic hep-
atitis infections. Because of the growing rate of mortality from liver cancer, augmenting life expectancy, and increasing number of
the elderly in Iran, policy makers are more expected to adopt measures including hepatitis B vaccination or hepatitis C treatment.
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1. Background
Liver cancer is a lethal disease and major health threat
in all communities. Patients with liver cancer survive for
less than 1 year (1, 2). Further, it is the fourth major cause of
cancer-related mortality in the world (3).
According to the 2015 global burden of diseases (GBD)
study, liver cancer mortality rate doubled from 1990 to
2015 worldwide (4). This increasing trend of liver cancer
mortality is even more remarkable in developing coun-
tries, which have inadequate diagnostic tools and ineffi-
cient treatment policies (5). People in developing coun-
tries, largely in Asian continent, are at a higher risk for liver
cancer than people in western countries. Moreover, liver
cancer is more prevalent (five to 10 times) in these regions
(2, 4, 6). Recent increases in the incidence and mortality of
liver cancer can be attributed to alcoholism (7), viral hep-
atitis infections (2, 8), and non-alcoholic fatty liver disease
(NAFLD) (9), which is a consequence of lifestyle changes
over time. These changes have resulted in a significant in-
crease in the incidence of liver cancer worldwide.
Although the steps to reduce liver cancer have been dis-
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cussed previously (10), to the best of our knowledge, com-
prehensive population-based studies or precise published
evidence on the mortality rate in liver cancer by cause are
lacking at the national and provincial levels in Iran.
2. Objectives
To estimate liver cancer mortality rate, this study
aimed to demonstrate the epidemiologic trend of liver
cancer mortality rate by sex, age, and geographical distri-
bution from 1990 to 2015.
3. Methods
3.1. Sources of Data
We used the data from the Iranian death registration
system (DRS) collected through the national and subna-
tional burden of diseases (NASBOD) project (11), after ad-
dressing DRS incompleteness and misclassification and us-
ing demographic and statistical methods, to estimate the
liver cancer mortality rates. In addition, the data on the
age and sex distribution of the Iranian population and
urbanization ratio were extracted from the national cen-
suses, which were conducted by the statistical centre of
Iran (12). Moreover, covariates such as years of schooling
and wealth index were calculated from the household ex-
penditure and Income Surveys from 1990 to 2010, which
were conducted by the statistical center of Iran (12). Fi-
nally, we evaluated the annual liver cancer mortality rates,
as well as its patterns, and temporal trends, between 1990
and 2015. For the first time, we collected detailed data on
hepatitis B and C and alcohol consumption at the national
and provincial levels in Iran.
3.2. Definition
We used the 10th version of international classifica-
tion of diseases (ICD10) codes for defining the underlying
causes of death (13). These codes were based on the diag-
noses by physicians who completed the death certificates,
and there were no criteria applied to evaluate the ability of
physicians. Data from the ICD 10 codes were transformed
to GBD by a physician and verified by a senior physician. A
percentage of deaths in the subgroups C22-24 (malignant
neoplasm of liver and intrahepatic bile ducts) were propor-
tionally redistributed into liver cancer due to hepatitis B, C,
alcohol use, and other causes. These proportions were cal-
culated based on the data from the GBD 2010 study (14). The
data collected from the 2015 population in Iran were used
as the standard population in a direct age-standardized
approach to facilitate the statistical comparisons between
the provinces.
3.3. Demographic Modeling
A demographical model was used to solve the problem
of the incompleteness of data in the Iranian death regis-
tration system. To estimate child mortality, the complete
birth history (CBH) and summary of birth history (SBH)
were used. To analyze SBH, the maternal age cohort (MAC)
and maternal age period (MAP) methods were applied. The
generalized growth balance (GGB), synthetic extinct gen-
eration (SEG), and a mixture of the two methods (GGB-
SEG) were used for estimating the incompleteness of the
data on adult mortality. More detailed information on this
model has been reported previously (15, 16).
3.4. Statistical Modeling
Concisely, a two-stage model, incorporating the spa-
tiotemporal and Gaussian process regression models
(GPR), was used to estimate mortality rates. The age-spatio
temporal model solves the problem of misalignment in
the age and space and time of data, then GPR is employed
to extrapolate all-cause (age- and sex-specific) mortality
rates with a more reliable uncertainty during the men-
tioned time span (17, 18). Then, the fraction of each cause
of death was exerted in the all-cause mortality and ex-
trapolated using the spatiotemporal model. In addition,
a simulation was conducted to estimate the uncertainty
of predicted values. This combined algorithm is a valid
statistical method that has been described previously (19).
Addressing misclassification: to estimate the mortality
rates by cause, all-cause mortality rates were initially com-
puted via the mentioned statistical method, and then, di-
vided into cause-specific rates in proportion to the cause
fractions extracted from the original data. More detailed
information is available elsewhere (20). All graphs and
plots were set using R statistical software, version 3.1.2 (21).
In addition, the direct age-standardized approach was ap-
plied using the Epitools package in R (22).
4. Results
Generally, the age-standardized liver cancer mortality
rate in Iran increased more than four times from 1.18 (95%
uncertainty interval: 0.86 to 1.61) deaths per 100,000 per-
sons in 1990 to 5.66 (4.20 to 7.63) deaths per 100,000 per-
sons in 2015 (Table 1). Similarly, the number of deaths from
liver cancer also had an increasing pattern (supplemen-
tary file Appendix 1, 2). From 1990 to 2015, the male to fe-
male sex, age-standardized mortality ratio changed from
0.87 to 1.82. With increasing age, the liver cancer mortality
rate increased in both sexes. In 1990, the maximum liver
cancer mortality rate was observed among people older
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than 85 years of age, and it was 22.41 (95% uncertainty inter-
val: 16.48 to 30.49) per 100,000 persons, which increased
to 158.15 per 100,000 persons (95% uncertainty interval:
118.3 to 211.31) in 2015 (Figure 1). In addition, the percent-
age change in the liver cancer mortality rates from 1990 to
2015 increased in all age groups. The percentage change
was 515.07% in patients 30 to 35 years of age and 605.83%
in patients older than 85 years of age (Table 2).
At the provincial level, the highest and lowest age-
standardized mortality rates for liver cancer in 2015 was
8.79 (95% uncertainty interval: 6.82 to 11.32) and 2.96 (95%
uncertainty interval: 2.15 to 4.08), respectively. These rates
represent a 2.96 times greater rate in 2015 than in 1990.
The trend for the liver cancer mortality rate has obviously
been increasing in all provinces during the 26 years of
the study (Figure 2). The percentage change in the age-
standardized mortality rate at the provincial level varied
between 846.72% and 67.58%. In addition, the average
mortality rate slope has a diversion of 5.16 times in some
provinces during the 26-year study period. (Table 1 and Fig-
ure 3). The age-adjusted liver cancer mortality rate at the
provincial level was higher in men than in women in 2015.
The ratio nearly doubled in most provinces (Figure 4).
Generally, about 71% of liver cancer mortality cases at
the national level are due to hepatitis B and C infections.
On average, the liver cancer mortality rate due to hepati-
tis B was approximately equal to that of hepatitis C (Fig-
ure 5). The liver cancer mortality trend due to hepatitis B
increased from 0.39 per 100,000 persons in 1990 (95% un-
certainty interval: 0.28 to 0.54) to 2.02 (95% uncertainty
interval: 1.49 to 2.72) per 100,000 persons in 2015. It had
an increasing trend in all age group and both sexes. The
male-to-female sex ratio of liver cancer mortality rate due
to hepatitis B changed from 1.24 to 2.53 during the 26-year
study period. (Figure 5, supplementary file Appendix 1).
The trend of liver cancer mortality due to hepatitis C in-
creased from 0.49 (95% uncertainty interval: 0.35 to 0.67)
per 100,000 persons in 1990 to 2.10 (95% uncertainty in-
terval: 1.56 to 2.82) per 100,000 persons in 2015. It had
an increasing trend in all age groups and both sexes. We
could detect a higher liver cancer rate in provinces such as
Golestan that have a high prevalence of HBV, but there were
exceptions noted in the provinces of Sistan and Baluches-
tan. The male-to-female sex ratio of age-standardized liver
cancer mortality rate due to alcohol consumption and hep-
atitis C, respectively, increased from 0.91 and 0.68 to 1.71
and 1.46 during the 26-year study period.
4. Discussion
This study showed that the trend of age-standardized
liver cancer mortality rate at the national level increased
more than four times from 1990 to 2015 in Iran. An increas-
ing trend in almost all the provinces was observed. In ad-
dition, liver cancer due to hepatitis B, hepatitis C, alcohol
consumption, and other causes, similarly, had an increas-
ing trend during the 26-year study period. Majority of liver
cancer mortality rate at the national level is due to hepati-
tis B and C infection. The increase in liver cancer mortality
was observed in all ages and both sexes. In recent years, the
mortality rate has been higher in male patients than in fe-
male patients at the national and provincial levels.
To validate the results, we used the most up-to-date de-
mographic and statistical modeling to address the incom-
pleteness (15), misclassification, and cause-distribution of
the mortality data (19, 20, 23). The results of this study
are in line with the findings of previous national and in-
ternational studies and reports in Iran and the world (4,
24-26). An increasing trend of liver cancer mortality has
been reported in the United States, Japan, Australia, Scot-
land, France, and Italy, while a decreasing trend has been
observed in the United Kingdom in both sexes (24, 27). An
upward trend in all-cause liver cancer mortality, particu-
larly in older age groups, has been reported in the men-
tioned countries (28). The results of our study at the na-
tional level are consistent with the findings of a previous
study in Iran, which reported an increase in the pattern
of liver cancer mortality among people aged 70 years and
older. The mortality rate was 3.7 per 100,000 persons. The
trends were higher in men than in women, as the male-
to-female sex mortality ratio was 1.5, which is compatible
with our results for this province. However, the mentioned
study did not assess the risk factors and incompleteness
of the mortality data (24). In 2009, the estimated national
cancer mortality rate was 4.7 per 100,000 persons (29). The
age-standardized liver cancer incidence rate per 100,000
persons was 2.3 (95% uncertainty interval: 1.9 to 2.6) in men
and 1.6 (95% uncertainty interval: 1.2 to 1.9) in women in
Fars province in 2002. According to the mentioned report,
the rate of liver cancer incidence had an increasing trend,
but it did not report the mortality rate (30). As the sur-
vival of liver cancer is shorter than a year, we expect to
have the same trends of incidence and mortality. Studies
showed that globally the incidence of liver cancer is two
times higher in men than in women (31). The differences
between liver cancer mortality patterns in the two sexes,
which were observed in this study, are in line with our ex-
pectations (male-to-female sex ratio = 1.82). In addition, ac-
cording to a previous study in Iran, the trend of hepatitis C
as the main risk factor for liver cancer has increased more
in men than in women (32), which is parallel to our find-
ings. Apparently, the differences between the two sexes in
terms of the liver cancer mortality pattern are similar in
Iran and European countries (28). Similar to our study, re-
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Table 1. Global and Iran Province-Level Age Standardized Mortality Rate (per 100,000) for Both Sexes and Percent Change (∆)
National/Sub-National 1990 2010 2015 % ∆ 1990 to 2015
Iran 1.18 (0.86-1.61) 5.97 (4.52 - 7.9) 5.66 (4.2 - 7.63) 381.79
Markazi 1.45 (1.07 - 1.95) 8.79 (6.82 - 11.32) 8.79 (6.82 - 11.32) 506.06
Gilan 1.45 (1.08 - 1.95) 6.94 (5.3 - 9.09) 6.92 (5.2 - 9.2) 377.48
Mazandaran 1.27 (0.93 - 1.74) 6.57 (4.82 - 8.93) 6.4 (4.57 - 8.92) 403.05
Azarbaijan East 1.68 (1.26 - 2.23) 7.68 (5.99 - 9.85) 6.95 (5.34 - 9.03) 313.58
Azarbaijan West 2.01 (1.48 - 2.73) 6.03 (4.78 - 7.6) 5.24 (4.08 - 6.72) 160.88
Kermanshah 1.17 (0.89 - 1.55) 7 (5.51 - 8.92) 6.83 (5.28 - 8.84) 481.92
Khuzestan 0.63 (0.47 - 0.83) 4.47 (3.48 - 5.73) 4.7 (3.6 - 6.13) 646.99
Fars 0.95 (0.71 - 1.26) 4.89 (3.78 - 6.34) 5.1 (3.84 - 6.75) 438.06
Kerman 1.39 (1.06 - 1.83) 4.72 (3.7 - 6) 4.36 (3.35 - 5.69) 213.60
Khorasan, Razavi 1.25 (0.94 - 1.67) 7.08 (5.4 - 9.26) 6.22 (4.66 - 8.29) 396.41
Isfahan 1.01 (0.74 - 1.4) 6.37 (4.78 - 8.5) 6.6 (4.86 - 8.94) 551.35
Sistan and Baluchestan 0.65 (0.44 - 0.95) 3.13 (2.29 - 4.27) 2.96 (2.15 - 4.08) 358.74
Kordestan 1.8 (1.29 - 2.51) 7.4 (5.9 - 9.28) 6.3 (4.91 - 8.08) 251.02
Hamedan 1.29 (0.99 - 1.68) 7.79 (6.23 - 9.75) 7.88 (6.16 - 10.07) 508.98
Chahar Mahal and Bakhtiari 1.2 (0.9 - 1.6) 5.78 (4.53 - 7.36) 5.9 (4.55 - 7.64) 390.29
Lorestan 1.45 (1.06 - 1.97) 6.12 (4.89 - 7.64) 5.07 (3.96 - 6.48) 250.30
Ilam 1.31 (0.95 - 1.79) 6.43 (4.91 - 8.41) 6.38 (4.8 - 8.46) 387.38
Kohgiluyeh and Boyer - Ahmad 1.26 (0.89 - 1.78) 5.41 (4.07 - 7.2) 4.76 (3.53 - 6.4) 278.26
Bushehr 0.76 (0.55 - 1.05) 4.67 (3.57 - 6.08) 4.73 (3.52 - 6.35) 522.59
Zanjan 2.1 (1.48 - 2.98) 4.73 (3.41-6.56) 3.52 (2.36-5.23) 67.58
Semnan 1.22 (0.86 - 1.73) 7.79 (5.85-10.34) 7.87 (5.82-10.62) 545.98
Yazd 1.44 (1.08 - 1.93) 6.45 (4.96-8.37) 6.34 (4.78-8.4) 339.84
Hormozgan 0.52 (0.37 - 0.73) 3.51 (2.64-4.67) 4.15 (3.01-5.71) 698.24
Tehran 0.91 (0.6 - 1.39) 5.34 (3.62-7.86) 4.71 (3.15-7.02) 415.88
Ardebil 1.42 (1.05 -1.91) 6.08 (4.84-7.63) 5.72 (4.46-7.32) 303.54
Qom 1.06 (0.72 - 1.54) 4.95 (3.53-6.91) 4.66 (3.3-6.57) 341.14
Qazvin 1.31 (0.98 - 1.75) 7.58 (6.02 - 9.54) 6.94 (5.4 - 8.91) 431.25
Golestan 0.99 (0.75 - 1.31) 6.7 (5.24 - 8.55) 7.12 (5.44 - 9.29) 619.37
Khorasan, North 1.87 (1.36 - 2.57) 7.07 (5.43 - 9.21) 6.27 (4.7 - 8.34) 234.98
Khorasan, South 1.78 (1.3 - 2.44) 8.54 (6.48 - 11.24) 7.96 (5.93 - 10.65) 348.64
Alborz 0.61 (0.43 - 0.87) 5.47 (4.07 - 7.34) 5.81 (4.25 - 7.93) 846.72
ports from Asia have shown that the liver cancer mortal-
ity rate is 14.5 and 6.1 per 100,000 in men and women, re-
spectively (33). The rate of liver cancer demonstrates an
increasing trend until 50 years of age, and it may peak or
plateau after that in high risk regions like Southeast Asia or
West Africa. The trend of increasing liver cancer incidence
and mortality with increasing age is seen in Italy, United
Kingdom, and white Hispanic ethnic group, parallel to this
study. However, there was no explanation for the increased
rate in older age groups. Globally, the sex ratios of liver
cancer incidence, range from 1.4 to 3.34. The highest sex ra-
tio was observed, in particular, among those aged 60 to 70
years (27).
A study on the mortality of patients with liver cancer
was conducted in Iran in 2004, and its results were was
consistent with this study’s findings on the sex ratio and
4 Hepat Mon. 2018; 18(1):e62009.
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Figure 1. Mortality Rate in Female and Male by Age in 1990 and 2015
Figure 2. Liver Cancer Deaths Number from 1990 to 2015 by Province
increasing pattern of liver cancer mortality with increas-
ing age. This study indicated that even though Iran is in
a low-risk region for liver cancer, 40% of the liver cancer
cases might be under-reported. However, it did not address
the cause of upward trend of liver cancer in the elderly age
groups (34). In addition, a similar pattern was reported in
the Khuzestan province, which was similar to this study
(35). However, there were no reports on the other provinces
in Iran. It is recommended for future studies to assess the
policies of the provinces that have both a high liver cancer
mortality rate and a lower prevalence of hepatitis B and C
infections such as the provinces of Sistan and Baluchestan
for better national policy making.
The main etiology of primary liver cancer is hepatitis B
and C, alcohol consumption, and other risk factors, includ-
ing obesity. The attributed effects of risk factors vary across
different regions, depending on the epidemiologic distri-
bution and prevalence of the risk factors in each region
(25, 27, 30, 36-38). In the United States, Europe, and Japan,
22% of the cases of primary liver cancer are attributed to
hepatitis B, while 60% are attributed to hepatitis C, and
43% are attributed to alcohol consumption. In contrast, in
Asia and Africa, this pattern is completely different which
is due to a high prevalence of chronic viral infections. The
attributed shares of hepatitis B, hepatitis C, and alcohol
consumption in the incidence of liver cancer are 60%, 20%,
and 20%, respectively. This pattern is almost in line with
the results of this study in Iran (27). The main cause of
liver cancer in Saudi Arabia, according to different studies,
was hepatitis C. Hepatitis B was the main cause of liver can-
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Figure 3. Age-Adjusted Liver Cancer Mortality (Per 100,000) for Both Sexes in 1990, 2000, 2010, 2015.
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Figure 4. Age Adjusted Mortality Rate in Female and Male by Province in 1990 and 2015
cer in Yemen and Lebanon. Other Arabic countries, such
as Iraq, have no qualified studies on this issue. In neigh-
boring countries of Turkey, Pakistan, and Afghanistan, the
main etiology of liver cancer is different. In Pakistan, be-
fore 1998, the main cause was hepatitis B. After that time, a
transition to hepatitis C as the main cause was observed. In
Turkey, similar to Iran, the main cause of liver cancer was
initially hepatitis B, and then, it was hepatitis C. Unfortu-
nately, Afghanistan, similar to Iraq, had no validated stud-
ies on this issue. In Iran, we could not find a comprehensive
study on the risk factors of liver cancer. However, there was
a study in one of the southern provinces of Iran in 2005,
which indicated that the main cause of liver cancer was
hepatitis B, and the other risk factor were predominantly
seronegative. In North African countries the main cause
was predominantly hepatitis C, especially in Egypt, which
is the leading country in the world for the rate of hepatitis
C-seropositivity. The only exception was Sudan; the main
causes in this country were the seronegativity rate of HBV
or HCV and number of patients with hepatitis B (39, 40). As
the hepatitis B vaccination program has been operating in
Iran for more than two decades, there is a very low risk of
incidence of liver cancer due to hepatitis B infection dur-
ing childhood. The majority of chronic cases of hepatitis
infection occurring during early adulthood and older ages
are due to unsafe sexual contacts and blood transfusion or
6 Hepat Mon. 2018; 18(1):e62009.
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Figure 5. Cause Specific Liver Cirrhosis Mortality Age Adjusted Rate by Province in 1990 and 2010
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Table 2. Percent Change Mortality Rate From 1990 to 2015 in National Level By Age
Group
Age Group Mortality Rate
1990
Mortality Rate
2015
Percent Change
5 to 9 0.05 (0.03 - 0.08) 0.18 (0.12 - 0.28) 270.1
10 to 14 0.06 (0.04 - 0.09) 0.23 (0.15 - 0.35) 293.31
15 to 19 0.08 (0.05 - 0.11) 0.46 (0.32 - 0.67) 511.28
20 to 24 0.12(0.08 - 0.18) 0.77 (0.55 - 1.08) 538.07
25 to 29 0.15(0.1 - 0.22) 0.92 (0.65 - 1.3) 527.15
30 to 34 0.19(0.13 - 0.27) 1.14(0.82 - 1.6) 515.07
35 to 39 0.28 (0.19 - 0.39) 1.75 (1.27 - 2.39) 530.27
40 to 44 0.43 (0.31 - 0.6) 2.48 (1.82 - 3.36) 477.37
45 to 49 0.79 (0.57 - 1.1) 4.89 (3.61 - 6.6) 516.49
50 to 54 1.22 (0.89 - 1.68) 7.47 (5.53 - 10.12) 511.7
55 to 59 1.7 (1.23 - 2.36) 11.53 (8.48 - 15.65) 576.98
60 to 64 3.19 (2.32 - 4.4) 17.45 (13 - 23.47) 446.29
65 to 69 5.48 (4.01 - 7.5) 26.46 (19.87 -
35.25)
382.67
70 to 74 8.18 (6.04 - 11.09) 37.61 (28.43 -
49.87)
359.82
75 to 79 16.31 (12 - 22.18) 53.34 (39.87 -
71.33)
227.1
80 to 84 16.51 (12.26 - 22.23) 55.71 (41.59 -
74.59)
237.48
85 and more 22.41 (16.48 -
30.49)
158.15 (118.3 -
211.31)
605.73
other invasive procedures performed under unsterile con-
ditions (41, 42).
Liver cancer mortality is a function of long-term al-
cohol consumption. Alcohol consumption is expected to
have an impact on people of older ages because of the cu-
mulative effect of alcohol on liver cancer (31). This cumu-
lative effect depends on the development of alcohol con-
sumption epidemiology, and in Iran, this epidemiology
has not been developed due to Islamic laws, so alcohol is
not a major concern (43). Chronic hepatitis B and C infec-
tions are still among the predominant causes of liver can-
cer in Iran. As liver cancer mortality is increasing in most
of the provinces of Iran, particularly, in men and older age
groups, it is important to adopt screening measures ear-
lier (10) and to establish more effective preventive or treat-
ment policies, especially for high-risk groups. As an effec-
tive strategy for controlling the upward trend of liver can-
cer mortality is the early screening of high-risk population
groups. Effective screening of patients with hepatitis B and
C or alcoholic cirrhosis could result in the detection of liver
cancer during the early stages. Another strategy is antivi-
ral therapy, which has been shown to have a significant ef-
fect on reducing liver cancer by full remission of hepati-
tis C (44). However, this treatment method is expensive
for the public, and cost reduction should be considered by
policy makers. Hepatitis treatment plays a major role in
our country. It is estimated that over 15% - 40% of hepati-
tis B-infected patients in Iran are at risk for the develop-
ment of cirrhosis and liver cancer (24, 45). The third strat-
egy is hepatitis B vaccination. It reduced liver cancer inci-
dence rate by 80% among the younger generation in Tai-
wan (46). However, the impact of this intervention is not
reported in other Asian countries. It is probably because
the program has been recently introduced (47). However,
it has been suggested that the policies in Saudi Arabia for
controlling hepatitis B may be causing a shift to hepatitis
C as the main cause of liver cancer (39). The vaccination
program against hepatitis B in Iran has reached a cover-
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age level of 94% (25, 48), but its main effects on liver can-
cer mortality are expected to emerge in the future. The uti-
lization of treatment protocols could be more effective in
this situation and may reduce liver cancer mortality (24).
In Iran, alcohol consumption is forbidden, so we do not
have a reliable report on alcohol consumption, and most
drinkers use handmade, low-quality alcohol. Programs to
limit or stop alcohol consumption need to be established
for the public to increase the awareness about this risk fac-
tor, apart from the national laws. Increasing knowledge
may also be applied for dealing with low-fat diet intake.
At last, promoting a healthy lifestyle is another preven-
tive measure (43, 49). The epidemiologic changes of obe-
sity and NAFLD, especially in developing countries, must
be considered for future policy making in controlling liver
cancer due to seronegativity, especially in the developing
countries of the Middle East, like Turkey (50). However, the
metabolic risk factors associated with liver cancer were not
assessed in Iran. It is suggested to develop future studies to
assess these factors as well.
This study had some limitations. First, incompleteness
and misclassifications are commonly observed in mortal-
ity data, especially in low-quality registries; however, us-
ing the proper registration methods and appropriate diag-
nostic tools and treatments, misclassification and incom-
pleteness can be minimized. A low incidence of liver can-
cer is found in both metastatic and primary cancers (27, 51).
Further, given the low incidence of liver cancer in Iran (31),
this problem is trivial. However, the main strength of our
study is the use of the most up-to-date statistical model-
ing for minimizing misclassification and incompleteness,
determining cause distribution, and finding garbage and
null codes in mortality data. Second, primary liver cancer
mainly occurs concurrently with cirrhosis. This, may also
be present in the main causes and complications of cirrho-
sis and liver cancer in more than 90% of patients. It is a crit-
ical issue when estimating mortality time trends to com-
pare them at provincial levels (29). We should train clin-
icians to properly distinguish the mentioned diseases in
registering the cause of death certification. Third, we could
not discriminate liver cancer mortality causes by more de-
tailed factors such as obesity and amount of alcohol con-
sumption. Therefore, the reports on alcohol consumption
could have some residual confounding. The details on the
amount of alcohol consumption pattern were not avail-
able. It is recommended to conduct future studies on this
issue. Finally, the variations in liver cancer and potential
uncertainty (primary or secondary) make long-term inter-
pretation of the mortality trends difficult. However, the
other strength of our study is calculating the uncertainty
of the mortality rates at the national and provincial lev-
els, using appropriate statistical methods. Moreover, the
pattern of age-standardized liver cancer mortality rate in
Iran is consistent with mortality pattern reported by the
GBD (25). As the major strength of our study, we collected
the data on every available registered number of liver can-
cer deaths, and it enabled us to conduct a more detailed
exploration of the attributed causes of liver cancer mor-
tality in line with the GBD classification and models. The
results could be used in the national and provincial esti-
mates and illustrate a clear picture for improving preven-
tive and therapeutic policies and programs in this field.
4.1. Conclusions
Because of the high distribution of liver cancer risk
factors, increasing incidence of and mortality from liver
cancer, increasing level of life expectancy, and increasing
number of the elderly in Iran, policy makers are expected
to focus more on this issue. The American Cancer Society
has not issued recommendations for liver cancer screen-
ing. Therefore, to reduce and stop the increasing trend
of liver cancer mortality, the main risk factors for it must
be screened and controlled. It is better to adopt measures
and policies for better and effective treatment of the dis-
ease and utilize palliative strategies to reduce its mortal-
ity and morbidity. Reducing hepatitis B and C infections,
as the main causes of mortality from liver cancer, must
be the main concern in Iran. In addition to the continua-
tion of hepatitis B vaccination program, it is necessary to
re-evaluate the vaccination program and safety of blood
sources and to improve measures for controlling blood
quality, to implement training and education programs on
high-risk behavior and alcohol consumption especially for
young adults, and to utilize early and effective hepatitis C
treatment measures.
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